GP-01 No Child Left Behind: Evaluating Disparities in Pediatric Pharmacodynamic Data
Abstract
Introduction: Pediatric pharmacodynamics describes how drugs affect a child during development. Although adult pharmacodynamic data are readily available, few studies have compared how age and dosing impacts the activity of drugs in children. The current study was designed to explore how variations in dosing may impact pediatric pharmacodynamics.
Methods: Over 60 articles were evaluated, and pediatric data were obtained for four classes of drugs, which included antibiotics, analgesics, anti-inflammatory, and chemotherapy medications. Demographic, dosing, adverse effects, safety, and efficacy data were extracted from each publication. Standard adult data were obtained from pubchem.gov and reference.medscape.com. The data was evaluated to compare standard adult dosing data to pediatric data and changes in pharmacodynamics were determined.
Results: An extensive literature search was conducted to obtain pediatric data. Research suggests that pharmacodynamic data is often available for children in the age range of 4-14 years. Anti-inflammatory and analgesic medications showed similar dosing between pediatrics and adults compared to antibiotics and anti-cancer drugs. Although the pediatric data for most drugs demonstrated that the doses studied resulted in an effective treatment response when compared to the equivalent adult dose, the pharmacodynamics of some drugs differed with age.
Conclusion: Pediatric pharmacodynamic data gaps were often observed in younger (<4 >years) and older (>14 years) children. Research regarding adult pharmacodynamics and drug dosing are generally more comprehensive when compared to children. In conclusion, pediatric pharmacodynamics greatly informs proper drug dosing and efficacy, opening the door for greater improvements in future treatments.
GP-01 No Child Left Behind: Evaluating Disparities in Pediatric Pharmacodynamic Data
Introduction: Pediatric pharmacodynamics describes how drugs affect a child during development. Although adult pharmacodynamic data are readily available, few studies have compared how age and dosing impacts the activity of drugs in children. The current study was designed to explore how variations in dosing may impact pediatric pharmacodynamics.
Methods: Over 60 articles were evaluated, and pediatric data were obtained for four classes of drugs, which included antibiotics, analgesics, anti-inflammatory, and chemotherapy medications. Demographic, dosing, adverse effects, safety, and efficacy data were extracted from each publication. Standard adult data were obtained from pubchem.gov and reference.medscape.com. The data was evaluated to compare standard adult dosing data to pediatric data and changes in pharmacodynamics were determined.
Results: An extensive literature search was conducted to obtain pediatric data. Research suggests that pharmacodynamic data is often available for children in the age range of 4-14 years. Anti-inflammatory and analgesic medications showed similar dosing between pediatrics and adults compared to antibiotics and anti-cancer drugs. Although the pediatric data for most drugs demonstrated that the doses studied resulted in an effective treatment response when compared to the equivalent adult dose, the pharmacodynamics of some drugs differed with age.
Conclusion: Pediatric pharmacodynamic data gaps were often observed in younger (<4>years) and older (>14 years) children. Research regarding adult pharmacodynamics and drug dosing are generally more comprehensive when compared to children. In conclusion, pediatric pharmacodynamics greatly informs proper drug dosing and efficacy, opening the door for greater improvements in future treatments.